Pharmaceuticals
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Trend Stats
1-Month Return
+4.54%
3-Month Return
+4.87%
12-Month Return
+26.88%
Volatility Score
1.6
RSI
58.5
ST Trend
Neutral
LT Trend
Up
Short-Term Trend
Neutral
The Short-Term Trend is a metric that gauges an ETF's short-term price trend.
Long-Term Trend
Up
The Long-Term Trend is a metric that gauges an ETF's long-term price trend.
Performance
Pharmaceuticals
S&P 500 Index
Components
| Symbol | Company | Market Cap | 12 mo return Performance over the past 12 months | 3 mo return Performance over the past 3 months | 1 mo return Performance over the past month | Vol Score Our gauge of the ETF's recent volatility | ST Trend A metric that gauges an ETF's short-term price trend | LT Trend A metric that gauges an ETF's long-term price trend |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly & Co | $1.1T | +55.25% | +7.54% | +10.64% | 2.9 | Up | Up |
| JNJ | Johnson&Johnson | $635B | +41.68% | +2.25% | -1.99% | 2.4 | Down | Up |
| ABBV | AbbVie | $505B | +29.04% | +11.86% | +8.42% | 2.3 | Up | Up |
| MRK | Merck | $358B | +70.92% | +11.99% | -1.90% | 2.8 | Down | Up |
| NVS | Novartis Sp ADR | $287B | +19.43% | -3.22% | +5.89% | 1.7 | Neutral | Neutral |
| AZN | ASTRAZENECA | $266B | +4.71% | +2.59% | +5.00% | 2.1 | Up | Down |
| NVO | Nordisk Sp ADR-B | $172B | -22.71% | -17.91% | +2.31% | 1.8 | Down | Down |
| PFE | Pfizer | $171B | +29.79% | +22.17% | +6.56% | 1.9 | Up | Up |
| BMY | Bristol-MyersSqu | $126B | +46.51% | +0.99% | +1.58% | 3.1 | Down | Up |
| MCK | Mckesson | $117B | +25.33% | +21.51% | +13.66% | 2.3 | Up | Up |
| GSK | GSK Sp ADR | $102B | +21.53% | +0.92% | +2.09% | 2.0 | Neutral | Down |
| SNY | SANOFI SP ADR | $100B | -14.98% | -4.06% | -0.14% | 2.0 | Down | Down |
| TAK | TAKEDA PHARM SP ADR | $65B | +46.95% | +20.33% | +7.60% | 1.7 | Up | Up |
| COR | Cencora | $63B | +0.24% | +8.71% | +5.99% | 2.2 | Neutral | Up |
| TEVA | TEVA PHARMA IND | $46B | +107.97% | +26.40% | +1.03% | 2.8 | Neutral | Up |
| HLN | Haleon Sp ADR | $45B | +13.27% | +6.47% | +12.73% | 1.9 | Up | Up |
| ZTS | Zoetis-A | $33B | -43.41% | +8.66% | +13.15% | 2.2 | Up | Down |
| VTRS | Viatris | $21B | +80.08% | +4.95% | +5.14% | 2.8 | Up | Up |
| JAZZ | Jazz Pharmaceuti | $14B | +54.48% | -16.04% | -8.89% | 3.2 | Down | Down |
| ELAN | ELANC ANIML HLTH | $11B | +2.13% | -9.12% | -0.22% | 3.1 | Down | Down |
| CORT | Corcept Therapeu | $9.3B | +18.39% | -11.17% | -23.98% | 6.8 | Down | Up |
| AXSM | Axsome Therapeut | $7.6B | +11.96% | -39.95% | -25.02% | 4.7 | Down | Down |
| DFTX | DEFINIUM | $4.8B | +0.00% | -16.91% | -5.26% | 4.9 | Up | Up |
| OGN | Organon | $3.6B | +51.33% | +1.55% | +0.15% | 0.3 | Neutral | Up |
| PRGO | Perrigo | $2.2B | -18.62% | +61.27% | +15.32% | 4.3 | Up | Up |
| 0 | 0 | 0 | 0 | Bullish | Bullish |
